# A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

> **NCT04619433** · PHASE3 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
- **DRUG:** Camrelizumab;Pemetrexed and Carboplatin;Placebo

## Key facts

- **NCT ID:** NCT04619433
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-01
- **Primary completion:** 2025-08-16
- **Final completion:** 2025-08-16
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Terminated by Sponsor
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619433, "A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04619433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*